Initial experience with HydroPearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids
Abstract Background Uterine Artery Embolization (UAE) is a minimally invasive procedure used to treat symptomatic uterine fibroids. The HydroPearl Microsphere (Terumo Interventional Systems) is an embolic agent approved for UAE and other embolization procedures. The purpose of this article is to des...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-03-01
|
Series: | CVIR Endovascular |
Subjects: | |
Online Access: | https://doi.org/10.1186/s42155-021-00223-9 |
id |
doaj-668c8dc5717640e787006bee5e6e02d0 |
---|---|
record_format |
Article |
spelling |
doaj-668c8dc5717640e787006bee5e6e02d02021-04-04T11:41:07ZengSpringerOpenCVIR Endovascular2520-89342021-03-01411710.1186/s42155-021-00223-9Initial experience with HydroPearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroidsMatthew A. Patetta0Ari J. Isaacson1Jessica K. Stewart2Division of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina School of MedicineDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina School of MedicineDivision of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina School of MedicineAbstract Background Uterine Artery Embolization (UAE) is a minimally invasive procedure used to treat symptomatic uterine fibroids. The HydroPearl Microsphere (Terumo Interventional Systems) is an embolic agent approved for UAE and other embolization procedures. The purpose of this article is to describe our initial experience with HydroPearl for UAE in patients with symptomatic uterine fibroids. Twenty-one patients who underwent UAE using HydroPearl Microspheres at a single institution from May 1, 2018 to December 31, 2019 were included in the study. The electronic medical record (EMR) was reviewed for documentation of short- and long-term complications, as well as improvements in menorrhagia and bulk-type symptoms. We also describe unique attributes of the HydroPearl Microsphere that should be considered when utilizing this embolization particle for UAE. Results Of the 21 patients, 18 had a 3-month or later post-procedure follow-up documented in the EMR and were included in the analysis. The average time between the UAE procedure and the most recent clinical note was 145 days. Sixteen patients reported symptoms of menorrhagia and 13 reported bulk symptoms prior to the UAE procedure. On follow-up, 13/16 patients (81%) and 12/13 patients (92%) experienced improvement in menorrhagia and bulk symptoms, respectively. The only recorded complication was amenorrhea in 4 patients (22%) who had an average age of 51 years. Conclusions Several characteristics of HydroPearl Microsphere may prove helpful when considering these embolic particles for use in UAE. Our initial experience with this embolic agent suggest that the reatment response for menorrhagia and bulk symptoms are largely similar to success rates reported in the literature for other embolic agents. Larger studies are needed to evaluate the safety and efficacy of this embolic particle for this indication.https://doi.org/10.1186/s42155-021-00223-9UAEHydropearlMicrospheresEmbolizationUterine fibroids |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Matthew A. Patetta Ari J. Isaacson Jessica K. Stewart |
spellingShingle |
Matthew A. Patetta Ari J. Isaacson Jessica K. Stewart Initial experience with HydroPearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids CVIR Endovascular UAE Hydropearl Microspheres Embolization Uterine fibroids |
author_facet |
Matthew A. Patetta Ari J. Isaacson Jessica K. Stewart |
author_sort |
Matthew A. Patetta |
title |
Initial experience with HydroPearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids |
title_short |
Initial experience with HydroPearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids |
title_full |
Initial experience with HydroPearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids |
title_fullStr |
Initial experience with HydroPearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids |
title_full_unstemmed |
Initial experience with HydroPearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids |
title_sort |
initial experience with hydropearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids |
publisher |
SpringerOpen |
series |
CVIR Endovascular |
issn |
2520-8934 |
publishDate |
2021-03-01 |
description |
Abstract Background Uterine Artery Embolization (UAE) is a minimally invasive procedure used to treat symptomatic uterine fibroids. The HydroPearl Microsphere (Terumo Interventional Systems) is an embolic agent approved for UAE and other embolization procedures. The purpose of this article is to describe our initial experience with HydroPearl for UAE in patients with symptomatic uterine fibroids. Twenty-one patients who underwent UAE using HydroPearl Microspheres at a single institution from May 1, 2018 to December 31, 2019 were included in the study. The electronic medical record (EMR) was reviewed for documentation of short- and long-term complications, as well as improvements in menorrhagia and bulk-type symptoms. We also describe unique attributes of the HydroPearl Microsphere that should be considered when utilizing this embolization particle for UAE. Results Of the 21 patients, 18 had a 3-month or later post-procedure follow-up documented in the EMR and were included in the analysis. The average time between the UAE procedure and the most recent clinical note was 145 days. Sixteen patients reported symptoms of menorrhagia and 13 reported bulk symptoms prior to the UAE procedure. On follow-up, 13/16 patients (81%) and 12/13 patients (92%) experienced improvement in menorrhagia and bulk symptoms, respectively. The only recorded complication was amenorrhea in 4 patients (22%) who had an average age of 51 years. Conclusions Several characteristics of HydroPearl Microsphere may prove helpful when considering these embolic particles for use in UAE. Our initial experience with this embolic agent suggest that the reatment response for menorrhagia and bulk symptoms are largely similar to success rates reported in the literature for other embolic agents. Larger studies are needed to evaluate the safety and efficacy of this embolic particle for this indication. |
topic |
UAE Hydropearl Microspheres Embolization Uterine fibroids |
url |
https://doi.org/10.1186/s42155-021-00223-9 |
work_keys_str_mv |
AT matthewapatetta initialexperiencewithhydropearlmicrospheresforuterinearteryembolizationforthetreatmentofsymptomaticuterinefibroids AT arijisaacson initialexperiencewithhydropearlmicrospheresforuterinearteryembolizationforthetreatmentofsymptomaticuterinefibroids AT jessicakstewart initialexperiencewithhydropearlmicrospheresforuterinearteryembolizationforthetreatmentofsymptomaticuterinefibroids |
_version_ |
1721542504595062784 |